Novel MAO-B inhibitors. potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease

International Review of Neurobiology

Volumn 100, Issue , 2011, Pages 217-236

  Unzeta, Mercedes ^a   Sanz, Elisenda ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Antiapoptotic compounds; MAO B inhibitor; Neuroprotection; Parkinson's disease; PF9601N; Propargylamines

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BREFELDIN A; CASPASE 2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; DOPAMINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LEVODOPA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MONOAMINE OXIDASE B INHIBITOR; PF 9601N; PROTEIN BCL 2; PROTEIN P53; PUMA PROTEIN; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; [N (2 PROPYNYL) 2 (5 BENZYLOXY INDOLYL)METHYLAMINE];

APOPTOSIS; BOOK; CELL DEATH; CELL VIABILITY; DISEASE COURSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HUMAN; IMMUNOREACTIVITY; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SYMPTOMATOLOGY;

EID: 80053530118     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386467-3.00011-X     Document Type: Chapter

References (135)

1. Ahlskog J.E. I can't get no satisfaction: still no neuroprotection for Parkinson disease. Neurology 2007, 69:1476-1477.
2. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
3. Ahlskog J.E., Uitti R.J. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. Neurology 2010, 74:1143-1148.
4. Alves da Costa C., Checler F. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?. Cell. Signal 2011, 6:963-968.
5. Aminoff M.J. Treatment should not be initiated too soon in Parkinson's disease. Ann. Neurol. 2006, 59:562-564. (discussion 564-565).
6. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997, 12:25-31.
7. Avila M., Balsa M.D., Fernandez-Alvarez E., Tipton K.F., Unzeta M. The effect of side chain substitution at positions 2 and 3 of the heterocyclic ring of N-acetylenic analogues of tryptamine as monoamine oxidase inhibitors. Biochem. Pharmacol. 1993, 45:2231-2237.
8. Balsa D., Fernandez-Alverez E., Tipton K.F., Unzeta M. Monoamine oxidase inhibitory potencies and selectivities of 2-[N-(2-propynyl)-aminomethyl]-1-methyl indole derivatives. Biochem. Soc. Trans. 1991, 19:215-218.
9. Balsa D., Perez V., Fernandez-Alvarez E., Unzeta M. Kinetic behaviour of some acetylenic indolalkylamine derivatives and their corresponding parent amines. J. Neural Transm. Suppl. 1994, 41:281-285.
10. Bar-Am O., Weinreb O., Amit T., Youdim M.B. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005, 19:1899-1901.
11. Battaglia V., Sanz E., Salvi M., Unzeta M., Toninello A. Protective effect of N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine (PF9601N) on mitochondrial permeability transition. Cell. Mol. Life Sci. 2006, 63:1440-1448.
12. Bellik L., Dragoni S., Pessina F., Sanz E., Unzeta M., Valoti M. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim. Pol. 2010, 57:235-239.
13. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
14. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
15. Bretaud S., Allen C., Ingham P.W., Bandmann O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem. 2007, 100:1626-1635.
16. Burke R.E. Programmed cell death and new discoveries in the genetics of parkinsonism. J. Neurochem. 2008, 104:875-890.
17. Caslake R., Macleod A., Ives N., Stowe R., Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst. Rev. 2009, 4:CD006661.
18. Charriaut-Marlangue C., Ben-Ari Y. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 1995, 7:61-64.
19. Chen J.J., Swope D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007, 27:161S-173S.
20. Chen J.J., Swope D.M., Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin. Ther. 2007, 29:1825-1849.
21. Culmsee C., Mattson M.P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 2005, 331:761-777.
22. Cutillas B., Ambrosio S., Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett. 2002, 329:165-168.
23. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
24. DeGracia D.J., Montie H.L. Cerebral ischemia and the unfolded protein response. J. Neurochem. 2004, 91:1-8.
25. Dragoni S., Materozzi G., Pessina F., Frosini M., Marco J.L., Unzeta M., Sgaragli G., Valoti M. CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes. J. Pharm. Pharm. Sci. 2007, 10:473-485.
26. Duan W., Zhu X., Ladenheim B., Yu Q.S., Guo Z., Oyler J., Cutler R.G., Cadet J.L., Greig N.H., Mattson M.P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 2002, 52:597-606.
27. Eberhardt O., Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett. 2003, 139:135-151.
28. Esposito E., Di Matteo V., Di Giovanni G. Death in the substantia nigra: a motor tragedy. Expert Rev. Neurother. 2007, 7:677-697.
29. Factor S.A. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 2008, 5:164-180.
30. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J. Neurol. 2005, 252(Suppl. 4):IV37-IV42.
31. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
32. Fernandez H.H., Chen J.J. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol. 2007, 30:150-168.
33. Gálvez-Jiménez N. Parkinson's disease. Neurobiology of Disease 2007, 51-67. Elsevier Academic Press, Maryland Heights, MO, USA. S. Gilman (Ed.).
34. Haberle D., Szoko E., Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr. Med. Chem. 2002, 9:47-51.
35. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2875-2880.
36. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., Ruberg M., Agid Y., Hirsch E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 2001, 21:2247-2255.
37. Hartmann A., Mouatt-Prigent A., Vila M., Abbas N., Perier C., Faucheux B.A., Vyas S., Hirsch E.C. Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. Neurobiol. Dis. 2002, 10:28-32.
38. Hauser R.A. Early pharmacologic treatment in Parkinson's disease. Am. J. Manag. Care 2010, 16(Suppl Implications):S100-S107.
39. Heinonen E.H., Rinne U.K., Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol. Scand. Suppl. 1989, 126:113-118.
40. Hetz C., Russelakis-Carneiro M., Maundrell K., Castilla J., Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J. 2003, 22:5435-5445.
41. Hidestrand M., Oscarson M., Salonen J.S., Nyman L., Pelkonen O., Turpeinen M., Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 2001, 29:1480-1484.
42. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
43. Hoozemans J.J., Veerhuis R., Van Haastert E.S., Rozemuller J.M., Baas F., Eikelenboom P., Scheper W. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. 2005, 110:165-172.
44. Hoozemans J.J., van Haastert E.S., Eikelenboom P., de Vos R.A., Rozemuller J.M., Scheper W. Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 2007, 354:707-711.
45. Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 2007, 20:477-483.
46. Ilieva E.V., Ayala V., Jove M., Dalfo E., Cacabelos D., Povedano M., Bellmunt M.J., Ferrer I., Pamplona R., Portero-Otin M. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 2007, 130:3111-3123.
47. Ives N.J., Stowe R.L., Marro J., Counsell C., Macleod A., Clarke C.E., Gray R., Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004, 329:593.
48. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 1991, 14:153-197.
49. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S26-S36. (discussion S36-S28).
50. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004, 63:S13-S22.
51. Jenner P., Olanow C.W. The pathogenesis of cell death in Parkinson's disease. Neurology 2006, 66:S24-S36.
52. Kamada T., Chow T., Hiroi T., Imaoka S., Morimoto K., Ohde H., Funae Y. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab. Pharmacokinet. 2002, 17:199-206.
53. Karunakaran S., Saeed U., Mishra M., Valli R.K., Joshi S.D., Meka D.P., Seth P., Ravindranath V. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J. Neurosci. 2008, 28:12500-12509.
54. Kieburtz K., Ravina B. Why hasn't neuroprotection worked in Parkinson's disease?. Nat. Clin. Pract. Neurol. 2007, 3:240-241.
55. Kodama R., Kondo T., Yokote H., Jing X., Sawada T., Hironishi M., Sakaguchi K. Nuclear localization of glyceraldehyde-3-phosphate dehydrogenase is not involved in the initiation of apoptosis induced by 1-methyl-4-phenyl-pyridium iodide (MPP+). Genes Cells 2005, 10:1211-1219.
56. Kostrzewa R.M., Kostrzewa J.P., Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 2002, 23:57-63.
57. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., Burke W.J. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 2001, 30:924-931.
58. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007, 14:32-43.
59. Labat-Moleur F., Guillermet C., Lorimier P., Robert C., Lantuejoul S., Brambilla E., Negoescu A. TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement. J. Histochem. Cytochem. 1998, 46:327-334.
60. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984, 292:390-394.
61. Larner S.F., Hayes R.L., McKinsey D.M., Pike B.R., Wang K.K. Increased expression and processing of caspase-12 after traumatic brain injury in rats. J. Neurochem. 2004, 88:78-90.
62. Larner S.F., Hayes R.L., Wang K.K. Unfolded protein response after neurotrauma. J. Neurotrauma 2006, 23:807-829.
63. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 1995, 311:1602-1607.
64. Levy O.A., Malagelada C., Greene L.A. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 2009, 14:478-500.
65. Li M., Beg A.A. Induction of necrotic-like cell death by tumor necrosis factor alpha and caspase inhibitors: novel mechanism for killing virus-infected cells. J. Virol. 2000, 74:7470-7477.
66. Lin J.H., Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 1998, 35:361-390.
67. Lindholm D., Wootz H., Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006, 13:385-392.
68. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120:237-248.
69. Macleod A.D., Counsell C.E., Ives N., Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst. Rev. 2005, 3:CD004898.
70. Marconi R., Bonnet A.M., Vidailhet M., Agid Y. The IMAO-B MDL 72.974 A in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1992, 55:1096-1097.
71. Mattson M.P. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid. Redox Signal. 2006, 8:1997-2006.
72. Matus S., Lisbona F., Torres M., Leon C., Thielen P., Hetz C. The stress rheostat: an interplay between the unfolded protein response (UPR) and autophagy in neurodegeneration. Curr. Mol. Med. 2008, 8:157-172.
73. Melamed E., Offen D., Shirvan A., Djaldetti R., Barzilai A., Ziv I. Levodopa toxicity and apoptosis. Ann. Neurol. 1998, 44:S149-S154.
74. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 1996, 137:120-123.
75. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J. Neural Transm. 2000, 107:335-341.
76. Nair V.D., McNaught K.S., Gonzalez-Maeso J., Sealfon S.C., Olanow C.W. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 2006, 281:39550-39560.
77. Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B.A., Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403:98-103.
78. Naoi M., Maruyama W., Yi H., Akao Y., Yamaoka Y., Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson's disease intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl. 2007, 72:121-131.
79. Nicotra A., Parvez S. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol. Teratol. 2002, 24:599-605.
80. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., Hori S., Kakizuka A., Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002, 16:1345-1355.
81. Olanow C.W. The pathogenesis of cell death in Parkinson's disease-2007. Mov. Disord. 2007, 22(Suppl. 17):S335-S342.
82. Olanow C.W., Myllyla V.V., Sotaniemi K.A., Larsen J.P., Palhagen S., Przuntek H., Heinonen E.H., Kilkku O., Lammintausta R., Maki-Ikola O., Rinne U.K. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998, 51:825-830.
83. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
84. Pahwa R., Lyons K.E. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr. Med. Res. Opin. 2009, 25:841-849.
85. Perez V., Unzeta M. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem. Int. 2003, 42:221-229.
86. Perez V., Marco J.L., Fernandez-Alvarez E., Unzeta M. Kinetic studies of N-allenic analogues of tryptamine as monoamine oxidase inhibitors. J. Pharm. Pharmacol. 1996, 48:718-722.
87. Perez V., Marco J.L., Fernandez-Alvarez E., Unzeta M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol. 1999, 127:869-876.
88. Perier C., Bove J., Wu D.C., Dehay B., Choi D.K., Jackson-Lewis V., Rathke-Hartlieb S., Bouillet P., Strasser A., Schulz J.B., Przedborski S., Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc. Natl. Acad. Sci. USA 2007, 104:8161-8166.
89. Pizzinat N., Copin N., Vindis C., Parini A., Cambon C. Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359:428-431.
90. Prat G., Perez V., Rubi A., Casas M., Unzeta M. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. J. Neural Transm. 2000, 107:409-417.
91. Prodesfarma PF9601N un nuevo farmaco inhibidor de la MAO-B para el tratamiento de la Enfermedad de Parkinson 1997, Resúmenes de los estudios realizados. Centro de Investigación Prodesfarma.
92. Rao R.V., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004, 11:372-380.
93. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
94. Reijonen S., Putkonen N., Norremolle A., Lindholm D., Korhonen L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell Res. 2008, 314:950-960.
95. Riederer P., Youdim M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem. 1986, 46:1359-1365.
96. Ryoo H.D., Domingos P.M., Kang M.J., Steller H. Unfolded protein response in a Drosophila model for retinal degeneration. EMBO J. 2007, 26:242-252.
97. Sampaio C., Ferreira J.J. Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression. Nat. Rev. Neurol. 2010, 6:126-128.
98. Sanz E., Romera M., Bellik L., Marco J.I., Unzeta M. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease. Med. Sci. Monit. 2004, 10:BR477-BR484.
99. Sanz E., Quintana A., Battaglia V., Toninello A., Hidalgo J., Ambrosio S., Valoti M., Marco J.L., Tipton K.F., Unzeta M. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP(+)-treated SH-SY5Y human dopaminergic cells. J. Neurochem. 2008, 105:2404-2417.
100. Sanz E., Quintana A., Hidalgo J., Marco J.L., Unzeta M. PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] confers MAO-B independent neuroprotection in ER stress-induced cell death. Mol. Cell. Neurosci. 2009, 41:19-31.
101. Schapira A.H. Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol. 2008, 15(Suppl. 1):5-13.
102. Schapira A.H., Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann. Neurol. 2006, 59:559-562.
103. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
104. Schwarzschild M.A. Rasagiline in Parkinson's disease. N. Engl. J. Med. 2010, 362:658. (author reply 658-659).
105. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol. Med. 2003, 9:360-365.
106. Shoulson I. Where do we stand on neuroprotection? Where do we go from here?. Mov. Disord. 1998, 13(Suppl. 1):46-48.
107. Slodzinski H., Moran L.B., Michael G.J., Wang B., Novoselov S., Cheetham M.E., Pearce R.K., Graeber M.B. Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin. Neuropathol. 2009, 28:333-343.
108. Spierings D., McStay G., Saleh M., Bender C., Chipuk J., Maurer U., Green D.R. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science 2005, 310:66-67.
109. Stowe R., Ives N., Clarke C.E., Deane K., Wheatley K., Gray R., Handley K., Furmston A. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst. Rev. 2010, 7:CD007166.
110. Szegezdi E., Logue S.E., Gorman A.M., Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006, 7:880-885.
111. Tabakman R., Lecht S., Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?. Bioessays 2004, 26:80-90.
112. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 2000, 166:29-43.
113. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 1998, 44:S142-S148.
114. Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 2003, 110:509-515.
115. Terzioglu M., Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 2008, 275:1384-1391.
116. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 1993, 328:176-183.
117. The Parkinson Study Group Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. Ann. Neurol. 1996, 40:99-107.
118. The Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 2002, 59:1937-1943.
119. The Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004, 61:561-566.
120. The Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 2005, 62:241-248.
121. Thorburn A. Death receptor-induced cell killing. Cell. Signal. 2004, 16:139-144.
122. Trimmer P.A., Smith T.S., Jung A.B., Bennett J.P. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996, 5:233-239.
123. Valoti M. CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes. J. Pharm. Pharm. Sci. 2007, 10:473-485.
124. Valoti M., Fusi F., Frosini M., Pessina F., Tipton K.F., Sgaragli G.P. Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. Eur. J. Pharmacol. 2000, 391:199-206.
125. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:365-375.
126. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 2001, 21:9519-9528.
127. Waldmeier P., Bozyczko-Coyne D., Williams M., Vaught J.L. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem. Pharmacol. 2006, 72:1197-1206.
128. Wang H.Q., Takahashi R. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid. Redox Signal. 2007, 9:553-561.
129. Waters C.H., Sethi K.D., Hauser R.A., Molho E., Bertoni J.M. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 2004, 19:426-432.
130. Weinreb O., Amit T., Bar-Am O., Sagi Y., Mandel S., Youdim M.B. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. 2006, 70:457-465.
131. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 2004, 91:451-461.
132. Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M.B., Naoi M. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 2006, 113:21-32.
133. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
134. Zhou W., Hurlbert M.S., Schaack J., Prasad K.N., Freed C.R. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 2000, 866:33-43.
135. Ziv I., Zilkha-Falb R., Offen D., Shirvan A., Barzilai A., Melamed E. Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinson's disease?. Mov. Disord. 1997, 12:17-23.